This article has been updated from a previous version to reflect the research collaboration between the organizations.
According to 454, the Broad Institute will use the system to identify genomic mutations associated with various diseases such as cancer, diabetes, and heart disease.
"We hope this collaboration will lead not only to new insights into disease genomics, but also to the development of additional exciting applications for this promising technology," Chad Nusbaum, co-director of the Genome Sequencing and Analysis program at the Broad Institute, said in a statement.
Financial terms of the arrangement were not disclosed, but 454 said that the Broad Institute is the company's first customer for the commercially available version of the Genome Sequencer 20 system.
The company originally installed its system at the Broad in March.